248 related articles for article (PubMed ID: 30104123)
1. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.
Li A; Vigers T; Pyle L; Zemanick E; Nadeau K; Sagel SD; Chan CL
J Cyst Fibros; 2019 Jan; 18(1):144-149. PubMed ID: 30104123
[TBL] [Abstract][Full Text] [Related]
2. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
[TBL] [Abstract][Full Text] [Related]
3. Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients.
Thomassen JC; Mueller MI; Alejandre Alcazar MA; Rietschel E; van Koningsbruggen-Rietschel S
J Cyst Fibros; 2018 Mar; 17(2):271-275. PubMed ID: 29249670
[TBL] [Abstract][Full Text] [Related]
4. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
6. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
8. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.
Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J;
J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
[TBL] [Abstract][Full Text] [Related]
10. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
11. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.
Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M;
Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836
[TBL] [Abstract][Full Text] [Related]
12. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
Talamo Guevara M; McColley SA
Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
[TBL] [Abstract][Full Text] [Related]
13. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
[TBL] [Abstract][Full Text] [Related]
14. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
[TBL] [Abstract][Full Text] [Related]
15. Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis.
Gelzo M; Iacotucci P; Caputo M; Cernera G; Comegna M; Carnovale V; Corso G; Castaldo G
J Cyst Fibros; 2021 Jan; 20(1):e1-e6. PubMed ID: 32586737
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
Burgel PR; Munck A; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Lemonnier L; Dehillotte C; Da Silva J; Paillasseur JL; Hubert D;
Am J Respir Crit Care Med; 2020 Jan; 201(2):188-197. PubMed ID: 31601120
[No Abstract] [Full Text] [Related]
17. Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.
Misgault B; Chatron E; Reynaud Q; Touzet S; Abely M; Melly L; Dominique S; Troussier F; Ronsin-Pradel O; Gerardin M; Mankikian J; Cosson L; Chiron R; Bounyar L; Porzio M; Durieu I; Weiss L; Kessler R; Kessler L
J Cyst Fibros; 2020 Sep; 19(5):712-716. PubMed ID: 32201160
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
19. Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.
Colombo C; Foppiani A; Bisogno A; Gambazza S; Daccò V; Nazzari E; Leone A; Giana A; Mari A; Battezzati A
J Endocrinol Invest; 2021 Oct; 44(10):2213-2218. PubMed ID: 33586024
[TBL] [Abstract][Full Text] [Related]
20. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]